Assessing the relationship between fear of cancer recurrence and health care utilization in early-stage breast cancer survivors
The purpose of this study was to determine whether fear of cancer recurrence (FCR) is associated with greater health care utilization (HCU) in early-stage breast cancer survivors.
Three hundred early-stage breast cancer survivors diagnosed within the past 7 years reported on FCR as well as calls and visits to oncology providers and primary care providers during the preceding 3 months. Participants also reported on use of mental health services and psychotropic medications since diagnosis. Structural equation modeling was used to create a latent FCR factor and evaluate this factor as a predictor of various HCU outcomes controlling for age at diagnosis, years since diagnosis, generalized anxiety, objective risk of recurrence, and number of comorbidities.
FCR predicted more visits to both oncology providers (RR = 1.53, p = .002) and primary care providers (RR = 1.31, p = .013), as well as more phone calls to oncology providers (RR = 2.08, p = .007). FCR was not a significant predictor of phone calls to primary care providers (RR = 1.39, p = .054), utilization of mental health treatment (OR = 1.27, p = .362), or use of psychotropic medications (OR = 1.37, p = .178).
FCR was associated with increases in some types of HCU, which may reflect excessive medical reassurance-seeking and lead to unnecessary medical costs.
Implications for Cancer Survivors
FCR is a serious concern that warrants greater attention to reduce distress-related health care utilization. Utilization of mental health services to address FCR may represent higher-value health care.
KeywordsFear of recurrence Health care utilization Breast cancer Survivorship concerns Medical reassurance-seeking Health anxiety
This study was funded partially by a grant from the National Cancer Institute (R21 CA171921) and funds from the University of Delaware.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 8.Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19(10):3246–50. https://doi.org/10.1245/s10434-012-2525-x.CrossRefPubMedGoogle Scholar
- 11.Thewes B, Butow P, Bell ML, et al. Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer. 2012;20(11):2651–9. https://doi.org/10.1007/s00520-011-1371-x.CrossRefPubMedGoogle Scholar
- 12.Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehnert A. Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv. 2015;9(4):567–75. https://doi.org/10.1007/s11764-015-0434-2.CrossRefPubMedGoogle Scholar
- 16.Liu Y, Pérez M, Schootman M, Aft RL, Gillanders WE, Jeffe DB. Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat. 2011;130(1):165–73. https://doi.org/10.1007/s10549-011-1551-x.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Muthén LK, Muthén BO. Mplus User’s Guide. 7th ed. Los Angeles, CA: Muthén & Muthén; 1998.Google Scholar
- 23.Enders CK. Applied missing data analysis. New York: Guilford Press; 2010.Google Scholar
- 31.Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24. https://doi.org/10.1200/JCO.2012.42.8375.CrossRefPubMedGoogle Scholar
- 32.Smith MD, Saunders R, Stuckhardt L, McGinnis JM, editors. Best Care at Lower Cost: the path to continuously learning health Care in America. Washington, D.C: National Academies Press; 2012.Google Scholar
- 34.American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline update. ASCO Guidelines. www.asco.org/guidelines/breastfollowup. Published 2013.
- 35.Butow PN, Turner J, Gilchrist J, et al. Randomized trial of ConquerFear: a novel, theoretically based psychosocial intervention for fear of cancer recurrence. J Clin Oncol. 2017; JCO–2017Google Scholar
- 39.Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, et al. How accurate are self-reports? An analysis of self-reported healthcare utilization and absence when compared to administrative data. J Occup Environ Med. 2009;51(7):786–96. https://doi.org/10.1097/JOM.0b013e3181a86671.CrossRefPubMedPubMedCentralGoogle Scholar